利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.019 秒)

    Strain-Independent Amplification of Pathogens and Vaccines Thereto
    1.
    发明申请
    Strain-Independent Amplification of Pathogens and Vaccines Thereto 有权
    病原菌和疫苗的应变无关扩增

    公开(公告)号：US20080311155A1

    公开(公告)日：2008-12-18

    申请号：US11662828

    申请日：2005-09-14

    申请人： Charles Nicolette ,  Irina Tcherepanova ,  Jason Harris ,  Donald Healey

    发明人： Charles Nicolette ,  Irina Tcherepanova ,  Jason Harris ,  Donald Healey

    IPC分类号： A61K39/00 ,  C12N5/06 ,  C12N15/87 ,  C07H21/04 ,  C12P19/34 ,  A61P31/00

    CPC分类号： C07K14/005 ,  A61K39/21 ,  A61K2039/5154 ,  A61K2039/5156 ,  C12N7/00 ,  C12N2740/16041 ,  C12N2740/16234 ,  C12N2740/16334 ,  C12Q1/703

    摘要： This in invention relates to methods for the nucleic acid amplification of multiple variants (strains) of any pathogen present in a sample, and preferably in a sample from a pathogen infected individual. In preferred embodiments, the pathogen is a retrovirus, such as HIV. The amplified pathogen nucleic acid can be used to identify the pathogen variants present in a sample, to quantitate the pathogen present in a sample, and as a nucleic acid vaccine, or in the preparation of antigen presenting cell vaccines. Nucleic acids produced by the methods of the invention or the proteins encoded thereby can be used to transfect/load antigen presenting cells. The loaded antigen presenting cells can then be used as a vaccine for the treatment of pathogen infection. In another embodiment, nucleic acids produced by the methods of the invention can be used directly as nucleic acid vaccines without prior loading into antigen presenting cells.

    摘要翻译： 本发明涉及用于核酸扩增样品中存在的任何病原体的多种变体（菌株）的方法，优选来自病原体感染个体的样品。 在优选的实施方案中，病原体是逆转录病毒，例如HIV。 扩增的病原体核酸可用于鉴定样品中存在的病原体变体，以定量样品中存在的病原体，以及作为核酸疫苗或制备抗原呈递细胞疫苗。 通过本发明的方法产生的核酸或由其编码的蛋白质可用于转染/负载抗原呈递细胞。 然后将负载的抗原呈递细胞用作用于治疗病原体感染的疫苗。 在另一个实施方案中，通过本发明的方法产生的核酸可以直接用作核酸疫苗而不预先加载到抗原呈递细胞中。

    Immunoglobulin construct containing tumor- specific p53bp2 sequenes for eliciting an anti-tumor response
    2.
    发明申请
    Immunoglobulin construct containing tumor- specific p53bp2 sequenes for eliciting an anti-tumor response 审中-公开
    含有诱导抗肿瘤反应的肿瘤特异性p53bp2序列的免疫球蛋白构建体

    公开(公告)号：US20060099202A1

    公开(公告)日：2006-05-11

    申请号：US10473691

    申请日：2002-04-01

    申请人： Charles Nicolette ,  Daniel Soltis

    发明人： Charles Nicolette ,  Daniel Soltis

    IPC分类号： A61K39/395 ,  C07K16/44

    CPC分类号： C07K14/4746 ,  A61K39/00 ,  A61K2039/505 ,  C07K16/00 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2318/10 ,  C07K2319/00

    摘要： The present invention provides immunoglobulins specific for p53BP2 ligand polypeptides. In a preferred embodiment, the present invention provides a variant of an immunoglobulin variable domain, wherein the immunoglobulin variable domain contains (A) at least one CDR region and (B) framework regions flanking the CDR, and the variant includes: (a) the CDR region having added or substituted therein at least one binding sequence, and (b) the flaking framework regions, wherein the binding sequence is heterologous to the CDR and the binding sequence is derived from a human ligand having immunogenic properties relevant to human lung cancer. In a preferred embodiment, the binding sequence is an antigenic sequence. In a further preferred embodiment, the variant contains a variable domain lacking an intrachain disulfide bond.

    摘要翻译： 本发明提供了对p53BP2配体多肽特异性的免疫球蛋白。 在优选的实施方案中，本发明提供免疫球蛋白可变结构域的变体，其中所述免疫球蛋白可变结构域含有（A）至少一个CDR区和（B）CDR侧翼的构架区，并且所述变体包括：（a） CDR区域在其中添加或取代至少一个结合序列，和（b）片状构架区，其中结合序列与CDR是异源的，并且结合序列衍生自具有与人肺癌相关的免疫原性的人配体。 在优选的实施方案中，结合序列是抗原序列。 在另一优选实施方案中，变体含有缺少链内二硫键的可变结构域。

    Altered peptide ligands
    4.
    发明申请
    Altered peptide ligands 审中-公开
    改变肽配体

    公开(公告)号：US20050281834A1

    公开(公告)日：2005-12-22

    申请号：US11195842

    申请日：2005-08-03

    申请人： Charles Nicolette

    发明人： Charles Nicolette

    IPC分类号： C12N15/09 ,  A61K39/00 ,  A61K39/12 ,  A61P31/12 ,  A61P35/00 ,  C12Q1/02 ,  G01N33/566 ,  G01N33/569 ,  A61K39/38

    CPC分类号： G01N33/56972 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/53 ,  G01N33/566

    摘要： The present invention provides compositions comprising altered peptide ligands that elicit immune responses in a subject to a native peptide. This invention also provides methods to raise T cell populations as well as a substantially purified population of said T cells. Altered peptide ligands find application in a wide variety of immunomodulatory protocols, including methods to induce or increase an immune response, as well as in methods to suppress or reduce an undesirable immune response, to a corresponding natural epitope.

    摘要翻译： 本发明提供包含改变的肽配体的组合物，其在受试者中引起天然肽的免疫应答。 本发明还提供了提高T细胞群体以及基本纯化的所述T细胞群体的方法。 改变的肽配体发现应用于各种免疫调节方案，包括诱导或增加免疫应答的方法，以及抑制或减少不期望的免疫应答的方法到相应的天然表位。

    Strain-independent amplification of pathogens and vaccines thereto
    8.
    发明授权
    Strain-independent amplification of pathogens and vaccines thereto 有权
    病原体和疫苗的菌株无关扩增

    公开(公告)号：US09085807B2

    公开(公告)日：2015-07-21

    申请号：US11662828

    申请日：2005-09-14

    申请人： Charles Nicolette ,  Irina Tcherepanova ,  Jason Harris ,  Donald Healey

    发明人： Charles Nicolette ,  Irina Tcherepanova ,  Jason Harris ,  Donald Healey

    IPC分类号： A61K39/00 ,  A61K39/12 ,  C12N5/06 ,  C07H21/04 ,  C12Q1/70

    CPC分类号： C07K14/005 ,  A61K39/21 ,  A61K2039/5154 ,  A61K2039/5156 ,  C12N7/00 ,  C12N2740/16041 ,  C12N2740/16234 ,  C12N2740/16334 ,  C12Q1/703

    摘要： This in invention relates to methods for the nucleic acid amplification of multiple variants (strains) of any pathogen present in a sample, and preferably in a sample from a pathogen infected individual. In preferred embodiments, the pathogen is a retrovirus, such as HIV. The amplified pathogen nucleic acid can be used to identify the pathogen variants present in a sample, to quantitate the pathogen present in a sample, and as a nucleic acid vaccine, or in the preparation of antigen presenting cell vaccines. Nucleic acids produced by the methods of the invention or the proteins encoded thereby can be used to transfect/load antigen presenting cells. The loaded antigen presenting cells can then be used as a vaccine for the treatment of pathogen infection. In another embodiment, nucleic acids produced by the methods of the invention can be used directly as nucleic acid vaccines without prior loading into antigen presenting cells.

    摘要翻译： 本发明涉及用于核酸扩增样品中存在的任何病原体的多种变体（菌株）的方法，优选来自病原体感染个体的样品。 在优选的实施方案中，病原体是逆转录病毒，例如HIV。 扩增的病原体核酸可用于鉴定样品中存在的病原体变体，以定量样品中存在的病原体，以及作为核酸疫苗，或用于制备抗原呈递细胞疫苗。 通过本发明的方法产生的核酸或由其编码的蛋白质可用于转染/负载抗原呈递细胞。 然后将负载的抗原呈递细胞用作用于治疗病原体感染的疫苗。 在另一个实施方案中，通过本发明的方法产生的核酸可以直接用作核酸疫苗而不预先加载到抗原呈递细胞中。

    Antigenic gp 100 compounds for therapy and diagnosis and methods of using same
    10.
    发明申请
    Antigenic gp 100 compounds for therapy and diagnosis and methods of using same 审中-公开
    抗原gp 100化合物治疗和诊断及其使用方法

    公开(公告)号：US20060014668A1

    公开(公告)日：2006-01-19

    申请号：US11119502

    申请日：2005-04-29

    申请人： Charles Nicolette

    发明人： Charles Nicolette

    IPC分类号： A61K38/10 ,  C07K16/30 ,  C07K7/08 ,  C07H21/04 ,  C12P21/06

    CPC分类号： A61K39/0011 ,  A61K38/00 ,  C07K7/06 ,  C07K14/70596

    摘要： The present invention provides methods and compositions for detecting, diagnosing, prognosing and monitoring the progress of gp 100-related cancers and malignancies and kits for use in said methods. Further provided are methods for screening to identify agonists and antagonists of cancer antigens associated with gp 100 related cancers and malignancies.

    摘要翻译： 本发明提供了用于检测，诊断，预测和监测gp 100相关癌症和恶性肿瘤和用于所述方法的试剂盒的进展的方法和组合物。 还提供了筛选以鉴定与gp 100相关的癌症和恶性肿瘤相关的癌症抗原的激动剂和拮抗剂的方法。